Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Equity Ratio (2023 - 2025)

Historic Equity Ratio for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 0.94.

  • CG Oncology's Equity Ratio fell 303.54% to 0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.94, marking a year-over-year decrease of 303.54%. This contributed to the annual value of 0.97 for FY2024, which is 25730.72% up from last year.
  • Per CG Oncology's latest filing, its Equity Ratio stood at 0.94 for Q3 2025, which was down 303.54% from 0.96 recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Equity Ratio registered a high of 0.98 during Q1 2024, and its lowest value of 0.62 during Q4 2023.
  • Its 3-year average for Equity Ratio is 0.77, with a median of 0.97 in 2024.
  • As far as peak fluctuations go, CG Oncology's Equity Ratio surged by 25730.72% in 2024, and later crashed by 303.54% in 2025.
  • Over the past 3 years, CG Oncology's Equity Ratio (Quarter) stood at 0.62 in 2023, then skyrocketed by 257.31% to 0.97 in 2024, then fell by 3.04% to 0.94 in 2025.
  • Its Equity Ratio was 0.94 in Q3 2025, compared to 0.96 in Q2 2025 and 0.97 in Q1 2025.